130 related articles for article (PubMed ID: 18670853)
21. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
[TBL] [Abstract][Full Text] [Related]
22. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
[TBL] [Abstract][Full Text] [Related]
23. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.
Chang KJ; Kong CB; Cho WH; Jeon DG; Lee SY; Lim I; Lim SM
Skeletal Radiol; 2015 Apr; 44(4):529-37. PubMed ID: 25431093
[TBL] [Abstract][Full Text] [Related]
25. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
26. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.
Casey DL; Wexler LH; Fox JJ; Dharmarajan KV; Schoder H; Price AN; Wolden SL
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1136-42. PubMed ID: 25539372
[TBL] [Abstract][Full Text] [Related]
27. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
[TBL] [Abstract][Full Text] [Related]
29. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma.
Franzius C; Bielack S; Flege S; Sciuk J; Jürgens H; Schober O
J Nucl Med; 2002 Aug; 43(8):1012-7. PubMed ID: 12163625
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
32.
Oh C; Bishop MW; Cho SY; Im HJ; Shulkin BL
J Nucl Med; 2023 Jun; 64(6):842-851. PubMed ID: 37201958
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
Gaston LL; Di Bella C; Slavin J; Hicks RJ; Choong PF
Skeletal Radiol; 2011 Aug; 40(8):1007-15. PubMed ID: 21298431
[TBL] [Abstract][Full Text] [Related]
34. The correlation of Tc-99m MIBI scintigraphy and histological response in determining the percentage of tumor necrosis in osteosarcoma after preoperative chemotherapy.
Punyaratabandhu T; Wittayawongsaruji S; Rajchadara S; Thanakit V; Charoenvareekul S; Khunkitti N; Songpatanasilp T
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S53-62. PubMed ID: 16862675
[TBL] [Abstract][Full Text] [Related]
35. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
36. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
[TBL] [Abstract][Full Text] [Related]
37. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
[TBL] [Abstract][Full Text] [Related]
38. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas.
Lee SW; Nam SY; Im KC; Kim JS; Choi EK; Ahn SD; Park SH; Kim SY; Lee BJ; Kim JH
Radiother Oncol; 2008 May; 87(2):211-6. PubMed ID: 18237806
[TBL] [Abstract][Full Text] [Related]
39. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
40. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
